{"name":"Pierre Fabre","slug":"pierre-fabre","ticker":"","exchange":"","domain":"pierre-fabre.com","description":"","hq":"Castres, France","founded":0,"employees":"","ceo":"","sector":"Dermatology / Oncology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2800000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1994-01-01","label":"Navelbine first approved","drug":"Navelbine","drugSlug":"vinorelbine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":25,"colorKey":"immunology","drugs":[{"name":"VERT-002","genericName":"VERT-002","slug":"vert-002","indication":"Other","status":"phase_1"},{"name":"DC071","genericName":"DC071","slug":"dc071","indication":"Other","status":"marketed"},{"name":"MPFF","genericName":"MPFF","slug":"mpff","indication":"Other","status":"phase_2"},{"name":"STX-241","genericName":"STX-241","slug":"stx-241","indication":"Other","status":"phase_1"},{"name":"Strefen","genericName":"Strefen","slug":"strefen","indication":"Other","status":"phase_2"},{"name":"Tamsulosine Arrow LP","genericName":"Tamsulosine Arrow LP","slug":"tamsulosine-arrow-lp","indication":"Benign prostatic hyperplasia with lower urinary tract symptoms","status":"marketed"},{"name":"Tamsulosine LP","genericName":"Tamsulosine LP","slug":"tamsulosine-lp","indication":"Other","status":"marketed"},{"name":"Bronchodilatator","genericName":"Bronchodilatator","slug":"bronchodilatator","indication":"Other","status":"phase_1"},{"name":"J022X ST","genericName":"J022X ST","slug":"j022x-st","indication":"Other","status":"phase_3"},{"name":"KIN-2787","genericName":"KIN-2787","slug":"kin-2787","indication":"Other","status":"phase_1"},{"name":"Phytotherapy","genericName":"Phytotherapy","slug":"phytotherapy","indication":"Other","status":"phase_2"},{"name":"Placebo matching Tamsulosine Arrow LP","genericName":"Placebo matching Tamsulosine Arrow LP","slug":"placebo-matching-tamsulosine-arrow-lp","indication":"Clinical trial control for benign prostatic hyperplasia studies","status":"marketed"},{"name":"Placebo matching Tamsulosine LP","genericName":"Placebo matching Tamsulosine LP","slug":"placebo-matching-tamsulosine-lp","indication":"Placebo control for clinical trials of Tamsulosin LP in benign prostatic hyperplasia","status":"marketed"},{"name":"Reference treatment : Nicotine transdermal patch","genericName":"Reference treatment : Nicotine transdermal patch","slug":"reference-treatment-nicotine-transdermal-patch","indication":"Other","status":"phase_1"},{"name":"Test treatment : V0116 transdermal patch","genericName":"Test treatment : V0116 transdermal patch","slug":"test-treatment-v0116-transdermal-patch","indication":"Other","status":"phase_1"},{"name":"V0018","genericName":"V0018","slug":"v0018","indication":"Other","status":"phase_2"},{"name":"V0057 - A mg","genericName":"V0057 - A mg","slug":"v0057-a-mg","indication":"Other","status":"phase_1"},{"name":"V0116 transdermal patch","genericName":"V0116 transdermal patch","slug":"v0116-transdermal-patch","indication":"Other","status":"phase_2"},{"name":"V0162","genericName":"V0162","slug":"v0162","indication":"Other","status":"phase_2"},{"name":"V0251","genericName":"V0251","slug":"v0251","indication":"Other","status":"phase_2"},{"name":"V0474 - A mg","genericName":"V0474 - A mg","slug":"v0474-a-mg","indication":"Other","status":"phase_1"},{"name":"V0474 - B mg","genericName":"V0474 - B mg","slug":"v0474-b-mg","indication":"Other","status":"phase_1"},{"name":"V0474 - C mg","genericName":"V0474 - C mg","slug":"v0474-c-mg","indication":"Other","status":"phase_1"},{"name":"V0498 - A mg","genericName":"V0498 - A mg","slug":"v0498-a-mg","indication":"Other","status":"phase_1"},{"name":"Vinorelbine cisplatin radiotherapy","genericName":"Vinorelbine cisplatin radiotherapy","slug":"vinorelbine-cisplatin-radiotherapy","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Navelbine","genericName":"vinorelbine","slug":"vinorelbine","indication":"Non-small cell lung cancer","status":"marketed"},{"name":"Binimetinib Oral Tablet","genericName":"Binimetinib Oral Tablet","slug":"binimetinib-oral-tablet","indication":"Melanoma","status":"phase_2"},{"name":"Encorafenib and Binimetinib","genericName":"Encorafenib and Binimetinib","slug":"encorafenib-and-binimetinib","indication":"Unresectable or metastatic melanoma with BRAF V600E or V600K mutation","status":"phase_3"},{"name":"F2695","genericName":"F2695","slug":"f2695","indication":"Advanced or metastatic solid tumors with FGFR alterations","status":"phase_3"},{"name":"V0034CR01B","genericName":"V0034CR01B","slug":"v0034cr01b","indication":"Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)","status":"phase_3"},{"name":"Vinflunine plus Capecitabine","genericName":"Vinflunine plus Capecitabine","slug":"vinflunine-plus-capecitabine","indication":"Advanced or metastatic transitional cell carcinoma of the urothelial tract","status":"phase_3"},{"name":"vinflunine and best supportive care","genericName":"vinflunine and best supportive care","slug":"vinflunine-and-best-supportive-care","indication":"Advanced or metastatic transitional cell carcinoma of the urothelial tract","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Locapred@","genericName":"Locapred@","slug":"locapred","indication":"Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)","status":"phase_3"},{"name":"RV3391A","genericName":"RV3391A","slug":"rv3391a","indication":"Dermatological indication (specific indication not publicly disclosed)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Locatop@","genericName":"Locatop@","slug":"locatop","indication":"Inflammatory skin conditions (eczema, dermatitis, psoriasis)","status":"phase_3"},{"name":"desonide 0.1% cream","genericName":"desonide 0.1% cream","slug":"desonide-0-1-cream","indication":"Eczema","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Amorolfine (Antifungal)","genericName":"Amorolfine (Antifungal)","slug":"amorolfine-antifungal","indication":"Onychomycosis (fungal nail infection)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"F17464","genericName":"F17464","slug":"f17464","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Navelbine","genericName":"vinorelbine","slug":"vinorelbine","phase":"marketed","mechanism":"Navelbine works by binding to the Substance-K receptor, disrupting microtubule formation and inhibiting cell division.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"VERT-002","genericName":"VERT-002","slug":"vert-002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DC071","genericName":"DC071","slug":"dc071","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Locapred@","genericName":"Locapred@","slug":"locapred","phase":"phase_3","mechanism":"Locapred is a topical corticosteroid that reduces inflammation and immune response in localized skin conditions.","indications":["Inflammatory skin conditions (specific indication in Phase 3 development unclear from available data)"],"catalyst":""},{"name":"Locatop@","genericName":"Locatop@","slug":"locatop","phase":"phase_3","mechanism":"Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors.","indications":["Inflammatory skin conditions (eczema, dermatitis, psoriasis)","Localized inflammatory dermatological disorders"],"catalyst":""},{"name":"MPFF","genericName":"MPFF","slug":"mpff","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"STX-241","genericName":"STX-241","slug":"stx-241","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Strefen","genericName":"Strefen","slug":"strefen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamsulosine Arrow LP","genericName":"Tamsulosine Arrow LP","slug":"tamsulosine-arrow-lp","phase":"marketed","mechanism":"Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.","indications":["Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Tamsulosine LP","genericName":"Tamsulosine LP","slug":"tamsulosine-lp","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"desonide 0.1% cream","genericName":"desonide 0.1% cream","slug":"desonide-0-1-cream","phase":"phase_3","mechanism":"Desonide is a topical corticosteroid that reduces inflammation by inhibiting the production of pro-inflammatory mediators.","indications":["Eczema","Psoriasis"],"catalyst":""},{"name":"Amorolfine (Antifungal)","genericName":"Amorolfine (Antifungal)","slug":"amorolfine-antifungal","phase":"marketed","mechanism":"Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane.","indications":["Onychomycosis (fungal nail infection)","Dermatophyte and non-dermatophyte fungal infections of the skin"],"catalyst":""},{"name":"Binimetinib Oral Tablet","genericName":"Binimetinib Oral Tablet","slug":"binimetinib-oral-tablet","phase":"phase_2","mechanism":"MEK1/2 inhibitor","indications":["Melanoma"],"catalyst":""},{"name":"Bronchodilatator","genericName":"Bronchodilatator","slug":"bronchodilatator","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Encorafenib and Binimetinib","genericName":"Encorafenib and Binimetinib","slug":"encorafenib-and-binimetinib","phase":"phase_3","mechanism":"Encorafenib and binimetinib are a combination of a BRAF inhibitor and a MEK inhibitor that block the MAPK signaling pathway in BRAF-mutant melanoma cells.","indications":["Unresectable or metastatic melanoma with BRAF V600E or V600K mutation","BRAF-mutant colorectal cancer (in combination, pipeline indication)"],"catalyst":""},{"name":"F17464","genericName":"F17464","slug":"f17464","phase":"phase_2","mechanism":"F17464 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"F2695","genericName":"F2695","slug":"f2695","phase":"phase_3","mechanism":"F2695 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cancer cells.","indications":["Advanced or metastatic solid tumors with FGFR alterations"],"catalyst":""},{"name":"J022X ST","genericName":"J022X ST","slug":"j022x-st","phase":"phase_3","mechanism":"J022X ST is a tyrosine kinase inhibitor that targets specific molecular pathways involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"KIN-2787","genericName":"KIN-2787","slug":"kin-2787","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phytotherapy","genericName":"Phytotherapy","slug":"phytotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo matching Tamsulosine Arrow LP","genericName":"Placebo matching Tamsulosine Arrow LP","slug":"placebo-matching-tamsulosine-arrow-lp","phase":"marketed","mechanism":"This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin Arrow LP, a selective alpha-1A adrenergic receptor antagonist used in benign prostatic hyperplasia treatment.","indications":["Clinical trial control for benign prostatic hyperplasia studies"],"catalyst":""},{"name":"Placebo matching Tamsulosine LP","genericName":"Placebo matching Tamsulosine LP","slug":"placebo-matching-tamsulosine-lp","phase":"marketed","mechanism":"This is a placebo formulation designed to match the appearance and administration profile of Tamsulosin LP (long-acting tamsulosin) for use in clinical trials.","indications":["Placebo control for clinical trials of Tamsulosin LP in benign prostatic hyperplasia"],"catalyst":""},{"name":"RV3391A","genericName":"RV3391A","slug":"rv3391a","phase":"phase_3","mechanism":"RV3391A is a topical agent developed for dermatological use, likely targeting inflammatory or proliferative skin conditions.","indications":["Dermatological indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"Reference treatment : Nicotine transdermal patch","genericName":"Reference treatment : Nicotine transdermal patch","slug":"reference-treatment-nicotine-transdermal-patch","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Test treatment : V0116 transdermal patch","genericName":"Test treatment : V0116 transdermal patch","slug":"test-treatment-v0116-transdermal-patch","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0018","genericName":"V0018","slug":"v0018","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0034CR01B","genericName":"V0034CR01B","slug":"v0034cr01b","phase":"phase_3","mechanism":"This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","indications":["Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)","Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)"],"catalyst":""},{"name":"V0057 - A mg","genericName":"V0057 - A mg","slug":"v0057-a-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0116 transdermal patch","genericName":"V0116 transdermal patch","slug":"v0116-transdermal-patch","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0162","genericName":"V0162","slug":"v0162","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0251","genericName":"V0251","slug":"v0251","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0474 - A mg","genericName":"V0474 - A mg","slug":"v0474-a-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0474 - B mg","genericName":"V0474 - B mg","slug":"v0474-b-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0474 - C mg","genericName":"V0474 - C mg","slug":"v0474-c-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"V0498 - A mg","genericName":"V0498 - A mg","slug":"v0498-a-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vinflunine plus Capecitabine","genericName":"Vinflunine plus Capecitabine","slug":"vinflunine-plus-capecitabine","phase":"phase_3","mechanism":"Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.","indications":["Advanced or metastatic transitional cell carcinoma of the urothelial tract"],"catalyst":""},{"name":"Vinorelbine cisplatin radiotherapy","genericName":"Vinorelbine cisplatin radiotherapy","slug":"vinorelbine-cisplatin-radiotherapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"vinflunine and best supportive care","genericName":"vinflunine and best supportive care","slug":"vinflunine-and-best-supportive-care","phase":"phase_3","mechanism":"Vinflunine is a chemotherapeutic agent that works by intercalating DNA and inhibiting the enzyme topoisomerase II, thereby inducing apoptosis in cancer cells.","indications":["Advanced or metastatic transitional cell carcinoma of the urothelial tract"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":38,"phaseCounts":{"marketed":7,"phase_1":11,"phase_3":10,"phase_2":10},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}